# Miltenyi Biomedicine GmbH clinical trials: 20 (2026)

ClinicalTrials.gov lists 20 trials with Miltenyi Biomedicine GmbH as lead sponsor, 14 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Miltenyi Biomedicine GmbH: 20 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/miltenyi-biomedicine-gmbh

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 14
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 21, 2026 | NCT07717164 | PRAISE-IR Versus CIBMTR Controls | Miltenyi Biomedicine GmbH | Observational | Not yet recruiting | ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome) | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717164) |
| May 6, 2026 | NCT07569965 | Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL | Miltenyi Biomedicine GmbH | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma (MCL) | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07569965) |
| December 17, 2025 | NCT07288879 | DALY II Japan/MB-CART2019.1 for DLBCL | Miltenyi Biomedicine GmbH | Phase 2 | Recruiting | DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07288879) |
| September 17, 2025 | NCT07178431 | MB-CART2019.1 in Refractory Multiple Sclerosis | Miltenyi Biomedicine GmbH | Phase 1/2 | Recruiting | Multiple Sclerosis, CAR T Cell Therapy | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07178431) |
| November 27, 2024 | NCT06708845 | US Zamto-cel Autoimmune Diseases | Miltenyi Biomedicine GmbH | Phase 1 | Recruiting | Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06708845) |
| July 18, 2024 | NCT06508931 | Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms | Miltenyi Biomedicine GmbH | Phase 2 | Recruiting | B-Cell Neoplasm | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06508931) |
| July 18, 2024 | NCT06508775 | Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies | Miltenyi Biomedicine GmbH | Not applicable | Recruiting | Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma, Acute Lymphatic... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06508775) |
| May 22, 2024 | NCT06424340 | MB-dNPM1-TCR.1 in Relapsed/Refractory AML | Miltenyi Biomedicine GmbH | Phase 1/2 | Recruiting | Leukemia, Myeloid, Acute | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06424340) |
| April 4, 2024 | NCT06347718 | CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease | Miltenyi Biomedicine GmbH | Phase 1/2 | Recruiting | Systemic Lupus Erythematosus, Systemic Sclerosis, Dermatomyositis, Polymyositis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06347718) |
| January 25, 2024 | NCT06225050 | M-2018-334 in Hematological Malignancies | Miltenyi Biomedicine GmbH | Not applicable | Recruiting | Hematological Malignancies | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06225050) |
| January 3, 2024 | NCT06189157 | MB-CART19.1 in Refractory SLE | Miltenyi Biomedicine GmbH | Phase 1/2 | Recruiting | SLE - Systemic Lupus Erythematosus | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06189157) |
| November 3, 2023 | NCT06116110 | Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU | Miltenyi Biomedicine GmbH | Observational | Recruiting | Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06116110) |
| April 14, 2021 | NCT04844866 | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | Miltenyi Biomedicine GmbH | Phase 2 | Recruiting | Diffuse Large B-cell Lymphoma | 213 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04844866) |
| March 11, 2021 | NCT04792489 | DALY II USA/ MB-CART2019.1 for DLBCL | Miltenyi Biomedicine GmbH | Phase 2 | Recruiting | Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma... | 315 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04792489) |
| May 28, 2020 | NCT04405466 | A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers | Miltenyi Biomedicine GmbH | Observational | Completed | COVID-19 | 417 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04405466) |
| March 27, 2019 | NCT03893019 | MB-CART20.1 Melanoma | Miltenyi Biomedicine GmbH | Early phase 1 | Terminated | Melanoma (Skin) | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03893019) |
| March 12, 2019 | NCT03870945 | Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) | Miltenyi Biomedicine GmbH | Phase 1 | Completed | B-cell Non Hodgkin Lymphoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03870945) |
| February 25, 2019 | NCT03853616 | MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) | Miltenyi Biomedicine GmbH | Phase 1 | Active not recruiting | Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03853616) |
| September 10, 2018 | NCT03664635 | MB-CART20.1 Lymphoma | Miltenyi Biomedicine GmbH | Phase 1/2 | Completed | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, B-cell... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03664635) |
| October 4, 2016 | NCT02923206 | Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis | Miltenyi Biomedicine GmbH | Not applicable | Completed | Preeclampsia | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02923206) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 3 |
| Phase 1/2 | 5 |
| Phase 2 | 5 |
| Not applicable | 3 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 12 |
| Completed | 4 |
| Not yet recruiting | 2 |
| Active not recruiting | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Lymphoma, B-Cell | 6 |
| Lymphoma, Non-Hodgkin | 5 |
| Lupus Erythematosus, Systemic | 3 |
| Lymphoma, Large B-Cell, Diffuse | 3 |
| Scleroderma, Systemic | 2 |
| Lymphoma, Mantle-Cell | 2 |
| Hematologic Neoplasms | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Melanoma | 2 |
| Multiple Sclerosis | 1 |
| Dermatomyositis | 1 |
| Polymyositis | 1 |
| Lupus Nephritis | 1 |
| Scleroderma, Diffuse | 1 |
| Autoimmune Diseases | 1 |
| Immune System Diseases | 1 |
| Recurrence | 1 |
| Dendritic Cell Sarcoma, Interdigitating | 1 |
| COVID-19 | 1 |
| Anemia, Refractory, with Excess of Blasts | 1 |
| Pre-Eclampsia | 1 |
| Premature Birth | 1 |
| Central Nervous System Neoplasms | 1 |
| Lymphoma | 1 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Contract law firms in the United States](https://specstream.ai/data/businesses/contract-law-firms/united-states)
- [T-shirt printers in the United States](https://specstream.ai/data/businesses/t-shirt-printers/united-states)
- [Irish pubs in the United States](https://specstream.ai/data/businesses/irish-pubs/united-states)
- [Burger restaurants in the United States](https://specstream.ai/data/businesses/burger-restaurants/united-states)
- [Road contractors in the United States](https://specstream.ai/data/businesses/road-contractors/united-states)
- [Guest houses in the United States](https://specstream.ai/data/businesses/guest-houses/united-states)
